NCT01807234View on ClinicalTrials.gov

Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine

PHASE4CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Migraines
Interventions
DRUG

Ketorolac

Single dose of Ketorolac (Sprix) nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.

DRUG

Sumatriptan

Sumatriptan (Imitrex) 20 mg one single dose of nasal spray for an acute migraine attack.

DRUG

Placebo

Placebo one spray in each nostril and placebo one nasal spray.

Trial Locations (1)

21224

The Johns Hopkins Bayview Headache Center, Baltimore

Sponsors

Collaborators (1)

American Regent, Inc.
All Listed Sponsors
collaborator

American Regent, Inc.

INDUSTRY

lead

Johns Hopkins University

OTHER

NCT01807234 - Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine | Biotech Hunter | Biotech Hunter